{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:47:45Z","timestamp":1787503665301,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-03867-4","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:01:41Z","timestamp":1716303701000},"page":"817-826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ten years\u2019 real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-7145","authenticated-orcid":false,"given":"Fernando","family":"Jerkovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Capalbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5217-3294","authenticated-orcid":false,"given":"Erika","family":"Abelleira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-7085","authenticated-orcid":false,"given":"Fabi\u00e1n","family":"Pitoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"issue":"6","key":"3867_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4158\/EP14466.DSCR","volume":"21","author":"L Davies","year":"2015","unstructured":"L. Davies, L.G. Morris, M. Haymart, A.Y. Chen, D. Goldenberg, J. Morris, J.B. Ogilvie, D.J. Terris, J. Netterville, R.J. Wong, G. Randolph; AACE Endocrine Surgery Scientific Committee, American Association of Clinical Endocrinologists and American College of endocrinology disease state clinical review: the increasing incidence of thyroid cancer. Endocr. Pract. 21(6), 686\u2013696 (2015). https:\/\/doi.org\/10.4158\/EP14466.DSCR","journal-title":"Endocr. Pract."},{"issue":"5","key":"3867_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","volume":"2","author":"M Schlumberger","year":"2014","unstructured":"M. Schlumberger, M. Brose, R. Elisei, S. Leboulleux, M. Luster, F. Pitoia, F. Pacini, Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2(5), 356\u2013358 (2014). https:\/\/doi.org\/10.1016\/S2213-8587(13)70215-8","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9940","key":"3867_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W. Smit, J. Chung, C. Kappeler, C. Pe\u00f1a, I. Moln\u00e1r, M.J. Schlumberger; DECISION investigators, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet 384(9940), 319\u2013328 (2014). https:\/\/doi.org\/10.1016\/S0140-6736(14)60421-9","journal-title":"Lancet"},{"issue":"7","key":"3867_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621\u2013630 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"3867_CR5","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","volume":"22","author":"MS Brose","year":"2021","unstructured":"M.S. Brose, B. Robinson, S.I. Sherman, J. Krajewska, C.C. Lin, F. Vaisman, A.O. Hoff, E. Hitre, D.W. Bowles, J. Hernando, L. Faoro, K. Banerjee, J.W. Oliver, B. Keam, J. Capdevila, Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22(8), 1126\u20131138 (2021). https:\/\/doi.org\/10.1016\/S1470-2045(21)00332-6","journal-title":"Lancet Oncol."},{"issue":"4","key":"3867_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"D.S. Hong, S.G. DuBois, S. Kummar, A.F. Farago, C.M. Albert, K.S. Rohrberg, C.M. van Tilburg, R. Nagasubramanian, J.D. Berlin, N. Federman, L. Mascarenhas, B. Geoerger, A. Dowlati, A.S. Pappo, S. Bielack, F. Doz, R. McDermott, J.D. Patel, R.J. Schilder, M. Tahara, S.M. Pfister, O. Witt, M. Ladanyi, E.R. Rudzinski, S. Nanda, B.H. Childs, T.W. Laetsch, D.M. Hyman, A. Drilon, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 21(4), 531\u2013540 (2020). https:\/\/doi.org\/10.1016\/S1470-2045(19)30856-3","journal-title":"Lancet Oncol."},{"issue":"6","key":"3867_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"S.G. Waguespack, A. Drilon, J.J. Lin, M.S. Brose, R. McDermott, M. Almubarak, J. Bauman, M. Casanova, A. Krishnamurthy, S. Kummar, S. Leyvraz, D.Y. Oh, K. Park, D. Sohal, E. Sherman, R. Norenberg, J.D. Silvertown, N. Brega, D.S. Hong, M.E. Cabanillas, Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur. J. Endocrinol. 186(6), 631\u2013643 (2022). https:\/\/doi.org\/10.1530\/EJE-21-1259","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"3867_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"R.C. Doebele, A. Drilon, L. Paz-Ares, S. Siena, A.T. Shaw, A.F. Farago, C.M. Blakely, T. Seto, B.C. Cho, D. Tosi, B. Besse, S.P. Chawla, L. Bazhenova, J.C. Krauss, Y.K. Chae, M. Barve, I. Garrido-Laguna, S.V. Liu, P. Conkling, T. John, M. Fakih, D. Sigal, H.H. Loong, G.L. Buchschacher Jr, P. Garrido, J. Nieva, C. Steuer, T.R. Overbeck, D.W. Bowles, E. Fox, T. Riehl, E. Chow-Maneval, B. Simmons, N. Cui, A. Johnson, S. Eng, T.R. Wilson, G.D. Demetri; trial investigators, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21(2), 271\u2013282 (2020). https:\/\/doi.org\/10.1016\/S1470-2045(19)30691-6","journal-title":"Lancet Oncol."},{"issue":"9","key":"3867_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"L.J. Wirth, E. Sherman, B. Robinson, B. Solomon, H. Kang, J. Lorch, F. Worden, M. Brose, J. Patel, S. Leboulleux, Y. Godbert, F. Barlesi, J.C. Morris, T.K. Owonikoko, D.S.W. Tan, O. Gautschi, J. Weiss, C. de la Fouchardi\u00e8re, M.E. Burkard, J. Laskin, M.H. Taylor, M. Kroiss, J. Medioni, J.W. Goldman, T.M. Bauer, B. Levy, V.W. Zhu, N. Lakhani, V. Moreno, K. Ebata, M. Nguyen, D. Heirich, E.Y. Zhu, X. Huang, L. Yang, J. Kherani, S.M. Rothenberg, A. Drilon, V. Subbiah, M.H. Shah, M.E. Cabanillas, Efficacy of selpercatinib in RET-altered thyroid cancers. N. Engl. J. Med. 383(9), 825\u2013835 (2020). https:\/\/doi.org\/10.1056\/NEJMoa2005651","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"3867_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"V. Subbiah, M.I. Hu, L.J. Wirth, M. Schuler, A.S. Mansfield, G. Curigliano, M.S. Brose, V.W. Zhu, S. Leboulleux, D.W. Bowles, C.S. Baik, D. Adkins, B. Keam, I. Matos, E. Garralda, J.F. Gainor, G. Lopes, C.C. Lin, Y. Godbert, D. Sarker, S.G. Miller, C. Clifford, H. Zhang, C.D. Turner, M.H. Taylor, Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 9(8), 491\u2013501 (2021). https:\/\/doi.org\/10.1016\/S2213-8587(21)00120-0","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"3867_CR11","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"N.L. Busaidy, B. Konda, L. Wei, L.J. Wirth, C. Devine, G.A. Daniels, J.A. DeSouza, M. Poi, N.D. Seligson, M.E. Cabanillas, J.A. Sipos, M.D. Ringel, A.K. Eisfeld, C. Timmers, M.H. Shah, Dabrafenib versus Dabrafenib + Trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid 32(10), 1184\u20131192 (2022). https:\/\/doi.org\/10.1089\/thy.2022.0115","journal-title":"Thyroid"},{"key":"3867_CR12","unstructured":"- FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. Jun 22, 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid."},{"issue":"1","key":"3867_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5306\/wjco.v13.i1.9","volume":"13","author":"F Pitoia","year":"2022","unstructured":"F. Pitoia, F. Jerkovich, P. Trimboli, A. Smulever, New approaches for patients with advanced radioiodine-refractory thyroid cancer. World J. Clin. Oncol. 13(1), 9\u201327 (2022). https:\/\/doi.org\/10.5306\/wjco.v13.i1.9","journal-title":"World J. Clin. Oncol."},{"issue":"3","key":"3867_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s12020-019-01883-3","volume":"64","author":"F Jerkovich","year":"2019","unstructured":"F. Jerkovich, M.G. Garc\u00eda Falcone, F. Pitoia, The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. Endocrine 64(3), 632\u2013638 (2019)","journal-title":"Endocrine"},{"issue":"4","key":"3867_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.20945\/2359-3997000000364","volume":"65","author":"N Treistman","year":"2021","unstructured":"N. Treistman, G.M. Nobre, M.Y. Tramontin, G.M.W. da Silva, D. Herchenhorn, L.H. de Lima Araujo, F.A. de Andrade, R. Corbo, D. Bulzico, F. Vaisman, Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors\u2014a single Brazilian center experience. Arch Endocrinol. Metab. 65(4), 411\u2013420 (2021). https:\/\/doi.org\/10.20945\/2359-3997000000364","journal-title":"Arch Endocrinol. Metab."},{"issue":"3","key":"3867_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s12020-014-0481-x","volume":"49","author":"M Gallo","year":"2015","unstructured":"M. Gallo, F. Michelon, A. Castiglione, F. Felicetti, A.A. Viansone, A. Nervo, C. Zichi, G. Ciccone, A. Piovesan, E. Arvat, Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center. Endocrine 49(3), 726\u2013734 (2015). https:\/\/doi.org\/10.1007\/s12020-014-0481-x","journal-title":"Endocrine"},{"issue":"3","key":"3867_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1089\/thy.2017.0356","volume":"28","author":"M Kim","year":"2018","unstructured":"M. Kim, T.H. Kim, D.Y. Shin, D.J. Lim, E.Y. Kim, W.B. Kim, J.H. Chung, Y.K. Shong, B.H. Kim, W.G. Kim; Korean Thyroid Cancer Study Group (KTCSG), Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: a Korean multicenter study. Thyroid 28(3), 340\u2013348 (2018). https:\/\/doi.org\/10.1089\/thy.2017.0356","journal-title":"Thyroid"},{"issue":"3","key":"3867_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1507\/endocrj","volume":"65","author":"K Sugino","year":"2018","unstructured":"K. Sugino, M. Nagahama, W. Kitagawa, K. Ohkuwa, T. Uruno, K. Matsuzu, A. Suzuki, C. Masaki, J. Akaishi, K.Y. Hames, C. Tomoda, Y. Ogimi, K. Ito, Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. Endocr. J. 65(3), 299\u2013306 (2018). https:\/\/doi.org\/10.1507\/endocrj","journal-title":"Endocr. J."},{"issue":"2","key":"3867_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1089\/thy.2019.0221","volume":"30","author":"C Masaki","year":"2020","unstructured":"C. Masaki, K. Sugino, N. Saito, J. Akaishi, K.Y. Hames, C. Tomoda, A. Suzuki, K. Matsuzu, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, K. Ito, Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences. Thyroid 30(2), 214\u2013221 (2020). https:\/\/doi.org\/10.1089\/thy.2019.0221","journal-title":"Thyroid"},{"issue":"6","key":"3867_CR20","doi-asserted-by":"publisher","first-page":"bvac048","DOI":"10.1210\/jendso\/bvac048","volume":"6","author":"S Hamidi","year":"2022","unstructured":"S. Hamidi, A. Boucher, B. Lemieux, G. Rondeau, R. Leb\u0153uf, L.G. Ste-Marie, X.K. Le, H. Mircescu, Lenvatinib therapy for advanced thyroid cancer: real-life data on safety, efficacy, and some rare side effects. J. Endocr. Soc. 6(6), bvac048 (2022). https:\/\/doi.org\/10.1210\/jendso\/bvac048","journal-title":"J. Endocr. Soc."},{"issue":"1","key":"3867_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/thy.2017.0205","volume":"28","author":"A Berdelou","year":"2018","unstructured":"A. Berdelou, I. Borget, Y. Godbert, T. Nguyen, M.E. Garcia, C.N. Chougnet, A. Ferru, C. Buffet, O. Chabre, O. Huillard, S. Leboulleux, M. Schlumberger, Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 28(1), 72\u201378 (2018). https:\/\/doi.org\/10.1089\/thy.2017.0205","journal-title":"Thyroid"},{"issue":"10","key":"3867_CR22","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.4158\/EP171822.OR","volume":"23","author":"S Jasim","year":"2017","unstructured":"S. Jasim, N.M. Iniguez-Ariza, C.R. Hilger, A.V. Chintakuntlawar, M.M. Ryder, J.C. Morris 3rd, K.C. Bible, Optimizing lenvatinib therapy in patients with metastatic radioactive iodine-resistant differentiated thyroid cancers. Endocr. Pract. 23(10), 1254\u20131261 (2017). https:\/\/doi.org\/10.4158\/EP171822.OR","journal-title":"Endocr. Pract."},{"key":"3867_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","volume":"118","author":"LD Locati","year":"2019","unstructured":"L.D. Locati, A. Piovesan, C. Durante, M. Bregni, M.G. Castagna, S. Zovato, M. Giusti, T. Ibrahim, E. Puxeddu, G. Fedele, G. Pellegriti, G. Rinaldi, D. Giuffrida, F. Verderame, F. Bertolini, C. Bergamini, A. Nervo, G. Grani, S. Rizzati, S. Morelli, I. Puliafito, R. Elisei, Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur. J. Cancer 118, 35\u201340 (2019). https:\/\/doi.org\/10.1016\/j.ejca.2019.05.031","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"3867_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1089\/thy.2019.0022","volume":"29","author":"EK Lee","year":"2019","unstructured":"E.K. Lee, S.M. Kim, B.H. Kim, M.J. Kim, D.J. Lim, M.H. Kim, D.Y. Shin, H.C. Kang, B.C. Ahn, S.W. Kim, H.Y. Ahn, Y.J. Park, Lesion-based evaluation predicts treatment response to lenvatinib for radioactive iodine-refractory differentiated thyroid cancer: a Korean multicenter retrospective study. Thyroid 29(12), 1811\u20131819 (2019). https:\/\/doi.org\/10.1089\/thy.2019.0022","journal-title":"Thyroid"},{"issue":"2","key":"3867_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/EJE-19-0763","volume":"182","author":"MD Aydemirli","year":"2020","unstructured":"M.D. Aydemirli, E. Kapiteijn, K.R.M. Ferrier, P.B. Ottevanger, T.P. Links, A.N.A. van der Horst-Schrivers, K.E. Broekman, R.H.H. Groenwold, J. Zwaveling, Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. Eur. J. Endocrinol. 182(2), 131\u2013138 (2020). https:\/\/doi.org\/10.1530\/EJE-19-0763","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"3867_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12020-020-02290-9","volume":"69","author":"F Jerkovich","year":"2020","unstructured":"F. Jerkovich, I. Califano, F. Bueno, J.M. Carrera, R. Giglio, E. Abelleira, F. Pitoia, Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. Endocrine 69(1), 142\u2013148 (2020). https:\/\/doi.org\/10.1007\/s12020-020-02290-9","journal-title":"Endocrine"},{"issue":"2","key":"3867_CR27","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.21873\/invivo.12350","volume":"35","author":"Y Ito","year":"2021","unstructured":"Y. Ito, N. Onoda, T. Kudo, H. Masuoka, T. Higashiyama, M. Kihara, A. Miya, A. Miyauchi, Sorafenib and lenvatinib treatment for metastasis\/recurrence of radioactive iodine-refractory differentiated thyroid carcinoma. In Vivo 35(2), 1057\u20131064 (2021). https:\/\/doi.org\/10.21873\/invivo.12350","journal-title":"In Vivo"},{"issue":"1","key":"3867_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/thy.2022.0054","volume":"33","author":"M Kim","year":"2023","unstructured":"M. Kim, M. Jin, M.J. Jeon, E.Y. Kim, D.Y. Shin, D.J. Lim, B.H. Kim, H.C. Kang, W.B. Kim, Y.K. Shong, H.K. Kim, W.G. Kim, Lenvatinib compared with Sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study. Thyroid 33(1), 91\u201399 (2023). https:\/\/doi.org\/10.1089\/thy.2022.0054","journal-title":"Thyroid"},{"issue":"8","key":"3867_CR29","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","volume":"20","author":"RI Haddad","year":"2022","unstructured":"R.I. Haddad, L. Bischoff, D. Ball, V. Bernet, E. Blomain, N.L. Busaidy, M. Campbell, P. Dickson, Q.Y. Duh, H. Ehya, W.S. Goldner, T. Guo, M. Haymart, S. Holt, J.P. Hunt, A. Iagaru, F. Kandeel, D.M. Lamonica, S. Mandel, S. Markovina, B. McIver, C.D. Raeburn, R. Rezaee, J.A. Ridge, M.Y. Roth, R.P. Scheri, J.P. Shah, J.A. Sipos, R. Sippel, C. Sturgeon, T.N. Wang, L.J. Wirth, R.J. Wong, M. Yeh, C.J. Cassara, S. Darlow, Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 20(8), 925\u2013951 (2022). https:\/\/doi.org\/10.6004\/jnccn.2022.0040","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"3867_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11154-023-09818-0","volume":"25","author":"F Pitoia","year":"2024","unstructured":"F. Pitoia, R.S. Scheffel, I. Califano, A. Gauna, H. Tala, F. Vaisman, A.R. Gonzalez, A.O. Hoff, A.L. Maia, Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective. Rev. Endocr. Metab. Disord. 25(1), 109\u2013121 (2024). https:\/\/doi.org\/10.1007\/s11154-023-09818-0","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"3867_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fendo.2019.00384","volume":"10","author":"SY Kim","year":"2019","unstructured":"S.Y. Kim, S.M. Kim, H. Chang, B.W. Kim, Y.S. Lee, H.S. Chang, C.S. Park, Safety of tyrosine kinase inhibitors in patients with differentiated thyroid cancer: real-world use of lenvatinib and Sorafenib in Korea. Front Endocrinol. (Lausanne) 10, 384 (2019). https:\/\/doi.org\/10.3389\/fendo.2019.00384","journal-title":"Front Endocrinol. (Lausanne)"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03867-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03867-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03867-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T08:01:58Z","timestamp":1722412918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03867-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3867"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03867-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4021318\/v1","asserted-by":"object"}]},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"F.P. is PI for Bayer, Exelixis, and Novartis, and speaker and consultant for Bayer and Raffo. The rest of the authors have no conflicts of interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}